KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other financing activities (2016 - 2023)

Ionis Pharmaceuticals (IONS) has 9 years of Other financing activities data on record, last reported at -$14.2 million in Q4 2023.

  • For Q4 2023, Other financing activities fell 229.42% year-over-year to -$14.2 million; the TTM value through Dec 2024 reached -$13.7 million, down 11.25%, while the annual FY2025 figure was $18.9 million, N/A changed from the prior year.
  • Other financing activities reached -$14.2 million in Q4 2023 per IONS's latest filing, down from $517000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $15.3 million in Q1 2021 and bottomed at -$14.2 million in Q4 2023.
  • Average Other financing activities over 5 years is $2.0 million, with a median of $490000.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: skyrocketed 1584.48% in 2019, then tumbled 2053.47% in 2022.
  • A 5-year view of Other financing activities shows it stood at $403000.0 in 2019, then tumbled by 3070.22% to -$12.0 million in 2020, then skyrocketed by 110.03% to $1.2 million in 2021, then skyrocketed by 812.75% to $11.0 million in 2022, then tumbled by 229.42% to -$14.2 million in 2023.
  • Per Business Quant database, its latest 3 readings for Other financing activities were -$14.2 million in Q4 2023, $517000.0 in Q3 2023, and $11.0 million in Q4 2022.